What is Prostamax? Prostate Health Peptide
Summary
Prostamax (KEDP) is a synthetic tetrapeptide investigated for chromatin decondensation and gene expression effects that may normalize age-related changes in cells, with preclinical data in lymphocytes and prostate models.
Substance Properties
What is Prostamax?
Prostamax is a short synthetic tetrapeptide (Lys-Glu-Asp-Pro or KEDP) studied for its ability to regulate chromatin structure and gene expression, particularly in immune cells and prostate-related models. It is not an approved therapy — it is a research compound for laboratory use only.
Mechanism of action: Chromatin decondensation
In experiments on human lymphocytes, Prostamax caused 'deheterochromatinization' of DNA — relaxation of condensed chromatin regions silenced with aging. This epigenetic change may allow reactivation of genes relevant to prostate function.
Preclinical data
Most data comes from in vitro studies on lymphocytes and tissue models. There are no published clinical trials in humans. Research relies mainly on the Khavinson group's work on peptide bioregulators.
Related Guides
Frequently Asked Questions (FAQ)
Is Prostamax suitable for prostate treatment?
No. Prostamax is exclusively a research compound. There are no clinical data supporting its therapeutic use.
References & Studies
Disclaimer
This article is exclusively educational for researchers. It does not constitute medical advice.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer